- Home
- AGCC vs GALT Comparison
AGCC vs GALT Comparison
Compare AGCC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGCC | GALT |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | AGCC | GALT |
|---|---|---|
| Price | $15.34 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 189.8K | ★ 340.3K |
| Earning Date | 04-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $168.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $1.15 |
| 52 Week High | $24.98 | $7.13 |
Technical Indicators
Market Signals| Indicator | AGCC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 39.67 |
| Support Level | $13.47 | $2.59 |
| Resistance Level | $24.98 | $3.32 |
| Average True Range (ATR) | 2.83 | 0.23 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 20.60 | 5.56 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.